Actinic (Solar) Keratosis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Actinic (Solar) Keratosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Actinic (Solar) Keratosis - Pipeline Review, H1 2016', provides an overview of the Actinic (Solar) Keratosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis
- The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects
- The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Actinic (Solar) Keratosis Overview 9
Therapeutics Development 10
Pipeline Products for Actinic (Solar) Keratosis - Overview 10
Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis 11
Actinic (Solar) Keratosis - Therapeutics under Development by Companies 12
Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes 14
Actinic (Solar) Keratosis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Actinic (Solar) Keratosis - Products under Development by Companies 19
Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes 21
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development 22
3M Drug Delivery Systems 22
Athenex, Inc. 23
Biofrontera AG 24
Digna Biotech, S.L. 25
Dolorgiet Gmbh & Co. Kg 26
Foamix Pharmaceuticals Ltd. 27
G&E Herbal Biotechnology Co., Ltd. 28
Galderma S.A. 29
Laboratories Ojer Pharma S.L. 30
LEO Pharma A/S 31
Novartis AG 32
Novelix Pharmaceuticals, Inc. 33
Oncology Research International Limited 34
Promius Pharma, LLC 35
SkyePharma Plc 36
Spherium Biomed S.L. 37
Valeant Pharmaceuticals International, Inc. 38
Actinic (Solar) Keratosis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
ACT-01 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AD-17137 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AK-3012 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
aminolevulinic acid hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
celecoxib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DFD-08 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
disitertide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
hydrogen peroxide + sulindac - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
IDP-125 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IDP-128 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
imiquimod - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
imiquimod SR - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
KX-01 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
LEO-43204 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
LFX-453 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NVX-207 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ORIL-007 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
resiquimod - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SKP-024 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule to Agonize TLR-7 and TLR-8 for Oncology, Allergic Rhinitis, Actinic Keratosis and Warts - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Activate Protein Kinase C for Dermatology and Oncology - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SP-12054 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SRT-100 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
VPE-001 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Actinic (Solar) Keratosis - Recent Pipeline Updates 79
Actinic (Solar) Keratosis - Dormant Projects 85
Actinic (Solar) Keratosis - Discontinued Products 87
Actinic (Solar) Keratosis - Product Development Milestones 88
Featured News & Press Releases 88
Feb 11, 2016: Biofrontera Announces, Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer 88
Jan 26, 2016: FDA completes Biofrontera's Ameluz NDA mid-cycle review 89
Dec 07, 2015: Swissmedic grants marketing approval for Ameluz in Switzerland 89
Oct 02, 2015: FDA determines May 10, 2016 as PDUFA date for Ameluz 89
Sep 22, 2015: Excellent long-term outcome with field treatment of actinic keratosis with Ameluz 90
Jun 22, 2015: Biofrontera completes final steps ahead of FDA New Drug Application in the USA 91
May 06, 2015: Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication 91
Mar 25, 2015: Biofrontera starts Sales and Marketing of Ameluz in Spain 92
Jan 26, 2015: Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz 92
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H1 2016 10
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Comparative Analysis by Unknown Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H1 2016 22
Actinic (Solar) Keratosis - Pipeline by Athenex, Inc., H1 2016 23
Actinic (Solar) Keratosis - Pipeline by Biofrontera AG, H1 2016 24
Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H1 2016 25
Actinic (Solar) Keratosis - Pipeline by Dolorgiet Gmbh & Co. Kg, H1 2016 26
Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 27
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 28
Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H1 2016 29
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma S.L., H1 2016 30
Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2016 31
Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2016 32
Actinic (Solar) Keratosis - Pipeline by Novelix Pharmaceuticals, Inc., H1 2016 33
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Limited, H1 2016 34
Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H1 2016 35
Actinic (Solar) Keratosis - Pipeline by SkyePharma Plc, H1 2016 36
Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H1 2016 37
Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 38
Assessment by Monotherapy Products, H1 2016 39
Assessment by Combination Products, H1 2016 40
Number of Products by Stage and Target, H1 2016 42
Number of Products by Stage and Mechanism of Action, H1 2016 44
Number of Products by Stage and Route of Administration, H1 2016 46
Number of Products by Stage and Molecule Type, H1 2016 48
Actinic (Solar) Keratosis Therapeutics - Recent Pipeline Updates, H1 2016 79
Actinic (Solar) Keratosis - Dormant Projects, H1 2016 85
Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H1 2016 86
Actinic (Solar) Keratosis - Discontinued Products, H1 2016 87